ScienceDex / Researcher record
Byrnes, Elizabeth M
- Northeastern University · Pharmacology (NIH department code)
From the FY2021 NIH awards this investigator leads as contact PI. The department is the award's.
- Top 5% Funded
NIH Funding · FY2021
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2001 | $79,250 | 1 | #28,422 |
| 2002 | $79,250 | 1 | #30,048 |
| 2021 | $6,693,512 | 1 | #460 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20011 record
- FY20021 record
- FY2021 · selected1 record
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2001 through FY2021Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2021 award categories
- Pharmacology
FY2021 award records by amount
NIH award records listing Byrnes, Elizabeth M as a PI. Multi-PI records show the full award amount for context.
- 1UG3DA050942-01A1UG3Contact PIAn Intranasal GDNF Gene Therapy for Opioid Relapse ReductionNortheastern University · Pharmacology (NIH department code)$6.7Maward amount
Award organization
Organizations that administered FY2021 awards listing Byrnes, Elizabeth M as a PI.
FY2021 award administered by Northeastern University (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2001First NIH AwardNortheastern University
- 2021$500K Cumulative Funding
- 2021$1M Cumulative Funding
- 2021$2M Cumulative Funding
- 2021$5M Cumulative Funding
- 2021Entered Top 50% NationallyRanked #460
- 2021Entered Top 25% NationallyRanked #460
- 2021Entered Top 10% NationallyRanked #460
- 2021Entered Top 5% NationallyRanked #460